Literature DB >> 2337680

Toxicity of novel anthracycline derivatives towards normal myeloid bone marrow progenitor cells (CFU-GM) is not increased by verapamil.

F W Busch1, U Schmittele, G Ehninger.   

Abstract

Drug-induced myelotoxicity is usually the dose-limiting factor of treatment of malignant tumors with cytostatic drugs. Suppression of in vitro myelopoiesis (CFU-GM) by cytostatics may be a suitable model reflecting the in vivo situation. Thus the inhibitory effects of the anthracyclines doxorubicin, theprubicin, idarubicin and cytorhodin S on CFU-GM were compared. Normal human bone marrow cells were incubated with these drugs for one hour and alternatively, for the whole culture period. For each substance and each incubation time a dose-response curve was established and the D50 determined. As certain calcium antagonists can increase the toxicity of some cytostatic drugs in various tumor models, the effect of the addition of verapamil (2 microM) was also investigated. It could be shown, that the myelotoxicity on CFU-GM of the drugs mentioned above was not increased after short-term or permanent exposure to this calcium antagonist.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2337680     DOI: 10.1007/bf01728787

Source DB:  PubMed          Journal:  Blut        ISSN: 0006-5242


  16 in total

1.  Inhibition of in vitro hematopoiesis by hepatitis A virus.

Authors:  F W Busch; S de Vos; B Flehmig; F Herrmann; C Sandler; A Vallbracht
Journal:  Exp Hematol       Date:  1987-10       Impact factor: 3.084

2.  Reversal of drug-resistance in multiple myeloma with verapamil.

Authors:  B G Durie; W S Dalton
Journal:  Br J Haematol       Date:  1988-02       Impact factor: 6.998

3.  Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients.

Authors:  R F Ozols; R E Cunnion; R W Klecker; T C Hamilton; Y Ostchega; J E Parrillo; R C Young
Journal:  J Clin Oncol       Date:  1987-04       Impact factor: 44.544

4.  Plasma pharmacokinetics of adriamycin and adriamycinol: implications for the design of in vitro experiments and treatment protocols.

Authors:  R F Greene; J M Collins; J F Jenkins; J L Speyer; C E Myers
Journal:  Cancer Res       Date:  1983-07       Impact factor: 12.701

5.  Effects of verapamil on etoposide, vincristine, and adriamycin activity in normal human bone marrow granulocyte-macrophage progenitors and in human K562 leukemia cells in vitro.

Authors:  J C Yalowich; J R Zucali; M Gross; W E Ross
Journal:  Cancer Res       Date:  1985-10       Impact factor: 12.701

6.  Clinical pharmacology and toxicity of 4'-O-tetrahydropyranyladriamycin.

Authors:  A A Miller; C G Schmidt
Journal:  Cancer Res       Date:  1987-03-01       Impact factor: 12.701

7.  Flow cytometric monitoring of cellular anthracycline accumulation in murine leukemic cells.

Authors:  A Krishan; A Sauerteig; K Gordon; C Swinkin
Journal:  Cancer Res       Date:  1986-04       Impact factor: 12.701

8.  Quantitation by flow cytometry of anthracycline drug uptake by peripheral blood and bone marrow cells in human leukemias.

Authors:  E Sahar; R Michalevicz; I Broudo; U Seligsohn
Journal:  Exp Hematol       Date:  1986-02       Impact factor: 3.084

9.  Clinically relevant concentrations of verapamil do not enhance the sensitivity of human bone marrow CFU-GM to adriamycin and VP16.

Authors:  M A Smith; S Merry; J G Smith; S B Kaye
Journal:  Br J Cancer       Date:  1988-06       Impact factor: 7.640

10.  9-alkyl anthracyclines. Absence of cross-resistance to adriamycin in human and murine cell cultures.

Authors:  C A Scott; D Westmacott; M J Broadhurst; G J Thomas; M J Hall
Journal:  Br J Cancer       Date:  1986-05       Impact factor: 7.640

View more
  3 in total

1.  The opposite effects of doxorubicin on bone marrow stem cells versus breast cancer stem cells depend on glucosylceramide synthase.

Authors:  Kaustubh N Bhinge; Vineet Gupta; Salman B Hosain; Seetharama D Satyanarayanajois; Sharon A Meyer; Benny Blaylock; Qian-Jin Zhang; Yong-Yu Liu
Journal:  Int J Biochem Cell Biol       Date:  2012-06-19       Impact factor: 5.085

2.  Effects of verapamil on the pharmacokinetics and metabolism of epirubicin.

Authors:  K Mross; K Hamm; D K Hossfeld
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

3.  Comparative toxicity of fostriecin, hepsulfam and pyrazine diazohydroxide to human and murine hematopoietic progenitor cells in vitro.

Authors:  D L Du; D A Volpe; C K Grieshaber; M J Murphy
Journal:  Invest New Drugs       Date:  1991-05       Impact factor: 3.850

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.